The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I/II study of sapacitabine and decitabine administered sequentially in elderly patients with newly diagnosed acute myeloid leukemia.
F. Ravandi
Honoraria - Eisai; Johnson & Johnson
Research Funding - Celgene; Eisai
S. Faderl
No relevant relationships to disclose
J. E. Cortes
Research Funding - Celgene; Eisai
G. Garcia-Manero
No relevant relationships to disclose
E. Jabbour
No relevant relationships to disclose
P. A. Boone
No relevant relationships to disclose
T. M. Kadia
No relevant relationships to disclose
G. Borthakur
No relevant relationships to disclose
W. G. Wierda
No relevant relationships to disclose
J. H. Chiao
Employment or Leadership Position - Cyclacel
Stock Ownership - Cyclacel
H. Kantarjian
Research Funding - Cyclacel; Eisai